Strategy

Oct 01, 2012
Pharmaceutical Executive
Pharm Exec takes a look at how a mid tier player Denmark's Lundbeck is counting on the momentum of the big US market to vault it to global leadership position.
Sep 01, 2012
Pharmaceutical Executive
High priced biologics may have a bright future in emerging markets, but winning access in the short term will be a hard sell.
Sep 01, 2012
Pharmaceutical Executive
Shareholder value now depends on finding pockets of "good" growth, in segments with fewer players, and where expenses can be tightly controlled.
Aug 29, 2012
By Pharmaceutical Executive Editors
world to improve the real world. The group brings value to over 150,000 customers of all sizes, in all industries, in more than 80 countries. For more information, visit www.3ds.com.
Aug 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
As the scope and complexity of registration information demanded by regulators increases, protection of that know-how has become a critical differentiator in the "go" or "no go" calculation on whether to invest in a new medicine.
Aug 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Planning for the long term is increasingly seen as an abstract absurdity. But a lasting business model is still possible—if you learn to adapt.
Aug 01, 2012
Pharmaceutical Executive
Creative non-pharmaceutical partnerships can offer innovators unique capabilities against the competition in a new era where challenges to market leadership are coming from every direction.
Aug 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020—just watch out for the harsh light of complacency.
Jul 01, 2012
Pharmaceutical Executive
In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises—change for pharma is here and its good.
Jul 01, 2012
Pharmaceutical Executive
Mastery of the clinical trial process has become essential to positioning new therapies for leadership in an increasingly crowded and lengthy race to registration.
native1_300x100
lorem ipsum